Akbari 2016.

Study characteristics
Methods	Study design: Randomized placebo controlled trial Masking: Double‐blind Number of arms: 2
Participants	Inclusion criteria: women with a diagnosis of PCOD based upon existence of 2 of the 3 criteria specified by Rotterdam, BMI > 25.2, LDL > 100, not pregnant, no other reasons for obesity and metabolic and hormone and glands and metabolism issues, no use of metformin and other medicines that create sensitivity to insulin and no use of OCP over the last three months and no consumption of medicines that reduce androgen, not sensitive to atorvastatin, and participants are 18 to 35 years old Exclusion criteria: pregnancy, using metformin or any other medicines that cause sensitivity to insulin and OCP over the last 3 months before the research and androgen reducer (using progesterone for withdrawal or keeping mensuration was ok), LDL < 100, BMI < 25, any hormonal or metabolic disorders not related to PCOS, any sensitivity to atorvastatin exhibited by the rise of liver enzymes more than three times the normal level and severe muscle cramps Baseline Characteristics Placebo n: 20 sex: female BMI: 26.3 Age:27.7 Total cholesterol: 224.5 mg/dL (5.81 mmol/L) LDL cholesterol: 138.3 mg/dl (3.58 mmol/L) HDL cholesterol: 50.2 mg/dL (1.30 mmol/L) Triglycerides: 182.4 mg/dL (2.06 mmol/L) Total testosterone: 0.69 nmol/L (19.90 ng/dL) Androstenedione: 2.3 DHEAS: 232.6 Left ovary size: 13.1 Right ovary size: 13.6 40 mg atorvastatin n: 20 sex: female BMI: 26.7 Age:30.9 Total cholesterol: 223.4 mg/dL (5.78 mmol/L) LDL cholesterol: 146.1 mg/dL (3.78 mmol/L) HDL cholesterol: 50.0 mg/dL (1.29 mmol/L) Triglycerides: 134.9 mg/dL (1.52 mmol/L) Total testosterone: 0.72 nmol/L (20.77 ng/dL) Androstenedione: 2.5 DHEAS: 225.3 Left ovary size: 14.9 Right ovary size: 15.1
Interventions	Intervention characteristics 40 mg/day for 6 weeks Placebo for 6 weeks
Outcomes	Total testosterone, DHEAS and androstenedione
Statistical analysis and reporting	Sequential nonrandom sampling method was used in both groups. The resulting information was analyzed using SPSS 16. As for qualitative variables, indicators such as frequency, mode, mean, and average were calculated. The frequency of qualitative variables was also measured. Independent t test was used to study qualitative variables, while repeated measures test was used to calculate the changes observed in two groups before and after intervention. Forward linear regression was used to study the confounding effect.
Number of participants lost to follow‐up	None
Source of funding	not reported
Notes	Location: clinic of Firouzgar Hospital, Tehran, Iran Ethical approval: The ethics committee of Iran University of Medical Sciences studied the ethical aspects of this research and approved it under the code 93/D/105/4431. The ethical principles specified in the Treaty of Helsinki were observed.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Used block randomization, but the process for selecting the blocks was not specified "People qualified for the research were randomly divided into randomised blocks containing 4 people in each one."
Allocation concealment (selection bias)	Unclear risk	Method of concealment is not described
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Objective outcomes like serum total testosterone, DHEAS and androstenedione are not likely to be influences by lack of blinding
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Androgen parameters were measured in a laboratory and the outcome measurements were not likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias): WDAEs	Unclear risk	Blinding method was not described
Selective reporting (reporting bias)	Unclear risk	No protocol was found, and there is insufficient information to judge if it is low or high risk of bias
Selective reporting (reporting bias) WDAEs	Low risk	WDAE outcome reported
Source of funding, sponsorship and conflict of interest	Unclear risk	Source of funding not reported
Incomplete outcome data (attrition bias): Total testosterone	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias): Androstenedione	Low risk	All participants were included in the efficacy analysis
Incomplete outcome data (attrition bias): DHEAS	Low risk	All participants were included in the efficacy analysis